×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Lecanemab CLARITY Open-Label Extension
clinical
2,301 words
KG: Lecanemab
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
topic:alzheimers
disease:alzheimers
Contents
Lecanemab CLARITY Open-Label Extension
Knowledge Graph
Related Hypotheses (30)
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
APOE Isoform Conversion Therapy
Score: 0.44
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
APOE-Dependent Autophagy Restoration
Score: 0.61
Multi-Modal Stress Response Harmonization
Score: 0.60
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.59
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.56
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
Purinergic Signaling Polarization Control
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.51
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
Senescence-Associated Myelin Lipid Remodeling
Score: 0.51
Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50
Autophagosome Maturation Checkpoint Control
Score: 0.49
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Show 25 more
Related Analyses (20)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Show 15 more
Related Experiments (5)
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Neural Stem Cell Therapy for Alzheimer's Disease
clinical · proposed · Score: 0.40
See Also (5)
Aducanumab (Aduhelm)
therapeutic · KG edge: targets
Dementia Australia
institution · KG edge: therapeutic_target
Alzheimer Indonesia
institution · KG edge: treats
APOE contributes to Alzheimer's disease by regulating b
hypothesis · KG edge: therapeutic_target
Amyloid-Related Imaging Abnormalities (ARIA)
entity · KG edge: implicated_in
Knowledge Graph (12 edges)
Lecanemab
treats
Early-Stage Alzheimer's Disease
Lecanemab
associated_with
Amyloid-Beta Clearance
Lecanemab
targets
Brain Amyloid Pathology
Lecanemab
causes
Amyloid Related Imaging Abnormalities
Lecanemab
causes
Microhemorrhages
Lecanemab
causes
Infusion Reactions
Lecanemab
causes
Macrohemorrhages
Lecanemab
targets
Amyloid-β
Lecanemab
targets
Amyloid Pathology
Lecanemab
targets
amyloid-β